American Heart Journal
Volume 156, Issue 4 , Pages 623-632 , October 2008

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

  • Robert M. Califf, MD

      Affiliations

    • Duke Transitional Medicine Institute, Durham NC
    • Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Robert M. Califf, MD, Duke Translational Medicine Institute, P.O. Box 17969, Durham, NC 27715.
    • ,
  • Mitradev Boolell, MD

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland
    • ,
  • Steven M. Haffner, MD

      Affiliations

    • University of Texas Health Science Center, San Antonio, TX
    • ,
  • M. Angelyn Bethel, MD

      Affiliations

    • Division of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC
    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • John McMurray, MD

      Affiliations

    • Department of Medicine, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
    • ,
  • Anil Duggal, MD

      Affiliations

    • Novartis Pharma Corp, East Hanover, NJ
    • ,
  • Rury R. Holman, FRCP

      Affiliations

    • Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK
    • ,
  • for the NAVIGATOR Study Group

      Affiliations

    • See Appendix A for executive committee members. As chair of the trial, Dr Califf takes responsibility for the content of this article.

Received 12 May 2004 ,Accepted 20 May 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study is funded by Novartis Pharma AG, Basel, Switzerland.

PII: S0002-8703(08)00389-X

doi: 10.1016/j.ahj.2008.05.017

American Heart Journal
Volume 156, Issue 4 , Pages 623-632 , October 2008

Article Tools

* Image Usage & Resolution